
Mike Ehlers
Biotech executive and neuroscientist Michael (Mike) Ehlers, MD, PhD — founding CEO and Board Chair of RNA exon-editing company Ascidian Therapeutics, recently appointed Chief Scientific Officer and Head of R&D at Formation Bio.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
Jun 12, 2026
Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers
14:08
14:22
14:30

Mike EhlersGUEST
So I'd say relative to other forms of RNA editing, the short answer is that most RNA editing is like fixing typos.

Mike EhlersGUEST
So traditional RNA editing like ADAR-based adenosine to inosine editing typically changes single nucleotides.

Mike EhlersGUEST
And that's powerful for point mutations, but doesn't necessarily scale well to diseases that are caused by large deletions, insertions, or complex mutations.
E
15:44Erin HarrisHOST
mike one of the things i always like to ask my guests is where they are what stage they're at with their clinical trials so can you talk to us a little bit about what the city is doing in terms of your clinical trials where we're at where we're headed